Companion Diagnostics Market - Size, Share, Outlook, and Opportunity Analysis, 2018 - 2026 Global Companion Diagnostics Market, By Application(Breast Cancer, Lung Cancer, Colorectal Cancer, Gastric Cancer, Melanoma), Technology(Immunohistochemistry, Real-time PCR, Gene Sequencing, FISH), and Geography - Trends, Analysis and Forecast till 2026 Personalized medicine is the new segment in discussion among healthcare experts around the globe. Also, encouragement from the regulatory bodies such as the FDA and EMEA in erms of providing a defined structure for companion diagnostic development is driving research activities in personalized medicine. Diagnosis at molecular level for each individual is of prime importance to identify the target biomarker before deciding the therapy. Companion diagnostic is one such emerging field for target biomarker identification reducing clinical trial cost and time to market the product. Pharmaceutical companies need to constantly innovate and integrate latest technological breakthroughs in order to sustain in the companion diagnostics market, given the looming threat of new technologies posing threat to existing product portfolio and research pipeline. Novartis AG focuses on R&D for biomarkers with the help of its partner SomaLogic, Inc., once they begin the process of finalizing the drug candidate. Such pre-work is now part of the routine of drug development, something that was an alien practice till around a decade ago. The U.S. FDA released a draft guideline for companion diagnostics in July 2016, providing a structure for the pharmaceutical companies to co-develop CDx test along with the drug therapies. Request Sample Copy of this Business Report @ https://www.coherentmarketinsights.com/insight/request-sample/109 Low cost and clinical benefits of companion diagnostics is expected to drive growth of the market The ecosystem of pharmaceuticals industry is one of the major factors driving growth of the companion diagnostics market. The providers of healthcare products and services, and patients who utilize these products and services is expected to be benefitted by a collaborative approach. The innovation of CDx helped drug developers in reducing the development costs, developing highly effective therapeutic products, and improving the time to market by identifying the
effectiveness of a drug against particular biomarkers. Moreover, better treatment outcomes and lower morbidity risk are benefits offered to the patients. Also, accurate diagnosis and determination of targeted cancer therapy has become much easier due to advanced technologies such as PCR, immunohistochemistry, and gene sequencing. Companion diagnostic (CDx) is a diagnostic tool used to determine the suitability of a drug therapy to the patient. It has become a critical part of targeted cancer therapy that allows for development of personalized therapy can be developed and administered to the patient. Whole blood samples, tissues samples, or buccal samples are collected and tested for diagnosis and identification of targeted disease biomarker. CDx is usually utilized in identifying genetic mutations and the health and treatment approach implications. In July 2016, the U.S. FDA released a draft guideline for development of a therapeutic product accompanying an IVD companion diagnostic. Companion diagnostics include Gleevec (imatinib mesylate) and BCR-ABL LDT and DAKO C-KIT PharmDx, Herceptin (trastuzumab) and DAKO Herceptest; and Nolvaldex (tamoxifen) and laboratory-developed estrogen receptor positive test. Companion diagnostics are beneficial for pharmaceutical companies who face challenges with respect to high drug development cost, safety and outcome of clinical trials, and long product approval time. Companion diagnostics lowers development costs, improves time to market and enhances drug safety by enabling rapid identification of target biomarker and the most effective drug therapy. For patients, the technology provides better treatment outcomes and lower morbidity risk. Use of technologies such as PCR, immunohistochemistry, and gene sequencing has enabled accurate diagnosis and determination of targeted cancer therapy. As the CDx tests also aid in revealing the off-target effects of a drug along with identification of a molecular target, CDx have become and indispensable tool for oncologists. Browse More About the Keyword Market Study @ https://www.coherentmarketinsights.com/market-insight/companion-diagnostics-market-109 Report includes chapters which deeply display the following deliverable about industry: • Global Companion Diagnostics Market Research Objective and Assumption • Global Companion Diagnostics Market Purview - Report Description, Executive Summary, and Coherent Opportunity Map (COM) • Global Companion Diagnostics Market Dynamics, Regulations, and Trends Analysis - Market Dynamics, Regulatory Scenario, Industry Trend, Merger and Acquisitions, New system Launch/Approvals, Value Chain Analysis, Porter’s Analysis, and PEST Analysis • Global Global Companion Diagnostics Market, By Regions • Global Companion Diagnostics Market Competition by Manufacturers including Production, Share, Revenue, Average Price, Manufacturing Base Distribution, Sales Area and Product Type. • Global Companion Diagnostics Market Manufacturers Profiles/Analysis including Company Basic Information, Manufacturing Base and Its Competitors. • Global Companion Diagnostics Market Manufacturing Cost Analysis including Key Raw Materials and Key Suppliers of Raw Materials.
• Industrial Chain, Sourcing Strategy and Downstream Buyers including Upstream Raw Materials Sourcing and Downstream Buyers • Marketing Strategy Analysis, Distributors/Traders including Marketing Channel, Market Positioning and Distributors/Traders List. • Market Effect Factors Analysis including Technology Progress/Risk, Consumer Needs/Customer Preference Change and Economic/Political Environmental Change. • Global Companion Diagnostics Market Forecast including Production, Consumption, Import and Export Forecast by Type, Applications and Region. • Research Findings and Conclusion Table of Contents of Keyword Market Report: 1. Research Objective and assumption 2. Market Purview 3. Market Dynamics, Regulations, and Trends Analysis 4. Keyword Market, By Advanced Water Meters, 2017 - 2025 (USD Million) 5. Keyword Market, By Service, 2017 - 2025 (USD Million) 6. Keyword Market, By Solution, 2017 - 2025 (USD Million) 7. Keyword Market, By Regions, 2017 - 2025 (USD Million) 8. Competitive Landscape Ask for Discount before Buying @ https://www.coherentmarketinsights.com/insight/request-discount/109 About Coherent Market Insights: Coherent Market Insights is a prominent market research and consulting firm offering action-ready syndicated research reports, custom market analysis, consulting services, and competitive analysis through various recommendations related to emerging market trends, technologies, and potential absolute dollar opportunity. Contact Us: Mr. Shah Coherent Market Insights 1001 4th Ave, #3200 Seattle, WA 98154 Tel: +1-206-701-6702 Email: firstname.lastname@example.org